You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 320 Phase IIa study of alpha-DC1 vaccine against HER2/HER3, chemokine modulation regimen and pembrolizumab in patients with asymptomatic brain metastasis from triple negative or HER2+ breast cancer

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
320 Phase IIa study of alpha-DC1 vaccine against HER2/HER3, chemokine modulation regimen and pembrolizumab in patients with asymptomatic brain metastasis from triple negative or HER2+ breast cancer

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020100011
Dec 20202608
Jan 20212404
Feb 20213007
Mar 20213608
Apr 20211607
May 2021206
Jun 20210010
Jul 2021008
Aug 20210018
Sep 20210011
Oct 202166017
Nov 202136016
Dec 20213802
Jan 202242010
Feb 20223605
Mar 20222805
Apr 20224403
May 202232019
Jun 20222008
Jul 20223008
Aug 20222407
Sep 20222009
Oct 2022806
Nov 20222209
Dec 20222407
Jan 20232405
Feb 20233600
Mar 20232809
Apr 20234608
May 20232201
Jun 20232204
Jul 20234605
Aug 20234409
Sep 20233405
Oct 20235605
Nov 20233602
Dec 20237605
Jan 20243002
Feb 20245602
Mar 202446037
Apr 20243603
May 20246406
Jun 20248003
Jul 20243405
Aug 20241603
Sep 20243209
Oct 20243406
Nov 20244604
Dec 202486013
Jan 20255606
Feb 202510012
Mar 2025005
Apr 20250013
May 2025004
Jun 2025007
Total18000427